Ladenburg Thalmann analyst Wangzhi Li upgraded Arcturus Therapeutics to Buy from Neutral with a $22 price target. By reaching a settlement with the appointment of four new independent directors and termination of all pending litigation, the company removed an organizational overhang since early February, Li tells investors in an intraday research note. The analyst is "encouraged" by the settlement agreement and management reinstatement. Li believes Arcturus can now focus on its normal operation to advance its Lunar and Una platforms, RNA therapeutics pipelines and multiple partnerships. The stock has "great upside potential," Li writes.